Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.

Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, Ala-Opas M, Kangasmäki A, Alanko T, Taipale L, Hervonen P, Bützow A, Virgolini I, Hemminki A.

Anticancer Res. 2016 Dec;36(12):6439-6447.

PMID:
27919966
2.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

3.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

4.

Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.

Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL; Finnprostate Group.

Scand J Urol. 2014 Dec;48(6):513-22. doi: 10.3109/21681805.2014.901410. Epub 2014 Mar 31.

PMID:
24679247
5.

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

Eur Urol. 2013 Jan;63(1):111-20. doi: 10.1016/j.eururo.2012.07.040. Epub 2012 Jul 27.

PMID:
22857983
6.

Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death.

Huang RC, Auvinen A, Hakama M, Tammela TL, Ala-Opas M, Leppilahti M, Vornanen T, Chen HH.

Health Expect. 2014 Dec;17(6):776-83. doi: 10.1111/j.1369-7625.2012.00802.x. Epub 2012 Jul 19.

7.

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C; SPCG-13.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):303-7.

PMID:
22546837
8.

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.

PMID:
22498230
9.

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group.

Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.

PMID:
22189383
10.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
11.

The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy.

Visapää H, Hotakainen K, Lundin J, Ala-Opas M, Stenman UH.

Urol Int. 2010;84(4):378-81. doi: 10.1159/000296302. Epub 2010 Mar 17.

PMID:
20299777
12.

Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.

Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A.

Int J Cancer. 2010 Oct 1;127(7):1650-9. doi: 10.1002/ijc.25165.

13.

False-positive screening results in the Finnish prostate cancer screening trial.

Kilpeläinen TP, Tammela TL, Määttänen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A.

Br J Cancer. 2010 Feb 2;102(3):469-74. doi: 10.1038/sj.bjc.6605512. Epub 2010 Jan 5.

14.

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.

Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A.

Br J Cancer. 2009 Sep 1;101(5):843-8. doi: 10.1038/sj.bjc.6605188. Epub 2009 Aug 4.

15.

Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors.

Mikkola A, Aro J, Rannikko S, Ruutu M; Finnprostate Group.

Scand J Urol Nephrol. 2009;43(4):265-70. doi: 10.1080/00365590902836500.

PMID:
19382005
16.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

17.

Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy.

Giordano S, Taskinen S, Sankila A, Ala-Opas M.

Scand J Urol Nephrol. 2008;42(4):392-4. doi: 10.1080/00365590701871575.

PMID:
19230174
18.

Biological aggressiveness of prostate cancer in the Finnish screening trial.

Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T, Määttänen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P.

Int J Cancer. 2009 Feb 1;124(3):547-52. doi: 10.1002/ijc.23873.

19.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
20.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.

Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.

PMID:
18432528

Supplemental Content

Loading ...
Support Center